Enhancement of anti-cancer compounds in fungal elicited-Oldenlandia umbellata culture
- PMID: 38916834
- DOI: 10.1007/s00210-024-03239-9
Enhancement of anti-cancer compounds in fungal elicited-Oldenlandia umbellata culture
Abstract
Our study focused on enhancing the production of anthraquinone derivatives in Oldenlandia umbellata using fungal elicitors. Aspergillus niger, Mucor prayagensis, and Trichoderma viride were used to elicit the anthraquinone derivatives in root cultures. The elicitation process led to an increase in the production of phytochemicals and secondary metabolites, with the highest total protein content observed in A. niger-elicited plants. We performed qualitative and quantitative phytochemical screening of the 80% methanol extract of the plants. Using reverse phase-ultra-fast liquid chromatography, we identified and quantified five anthraquinone compounds: aloe-emodin, rhein, emodin, chrysophanol, and alizarin. The in vitro root samples elicited with A. niger and M. prayagensis exhibited four and three anthraquinone derivatives, respectively, whereas those elicited with T. viride showed only two derivatives. Interestingly, chrysophanol content was the highest in A. niger-elicited root samples. We constructed a system pharmacology framework consisting of 40 nodes and 45 edges with 34 interacting genes. We also identified human proteins that interact with these derivatives, and inferred their roles in cancer-associated pathways. These anthraquinone derivatives interact with various proteins in multiple pathways, including apoptosis, human cytomegalovirus infection, proteoglycans in cancer, MAPK signaling, and hepatitis C, highlighting their potential therapeutic applications in cancer treatment.
Keywords: Oldenlandia umbellata; Anthroquinone; Anti-cancer; Network pharmacology; Phytochemicals; Plant cell culture.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Ethics approval and consent to participate: The need for ethical approval and individual consent are not required. Competing interests: The authors declare no competing interests.
References
-
- Al-Shuhaib MB, Al-Shuhaib JM (2023) Phytochemistry, pharmacology, and medical uses of Oldenlandia (family Rubaceae): a review. Naunyn-Schmiedeberg’s Arch Pharmacol 14:1–33
-
- Baque MA, Shiragi MH, Lee EJ, Paek KY (2012) Elicitor effect of chitosan and pectin on the biosynthesis of anthraquinones, phenolics and flavonoids in adventitious root suspension cultures of Morinda citrifolia (L.). Aust J Crop Sci 6:1349–55
-
- Bharti PK, Singh SK, Kumari S (2023) Elicitors: role in secondary metabolite production in medicinal plants. In Genetic Manipulation of Secondary Metabolites in Medicinal Plant. Singapore: Springer Nature Singapore. pp 147-178
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources